PBH — Stock Film
STOCK FILMSCENE 1/11PBH · $50.52
Stock Expert AI presents
PBH
Prestige Consumer Healthcare Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Prestige Consumer Healthcare Inc. A quick introduction.

On the stock market since 2005, it operates in the world of health and science. It has 890 employees. Now — the numbers.

on the stock market since 2005
890 employees
$2.4B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $17 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 17%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
24%Gastrointestinal
Gastrointestinal 24%Women's Health 21%Eye and Ear Care 13%Dermatologicals 12%Analgesics 10%Other 20%
24% of all revenue comes from a single line: Gastrointestinal.

Revenue is spread across several lines; no single product carries the company.

Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $981.6M. In times of high interest rates, a gap like that can squeeze a company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
84
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
30
very weak

Clearly below the class average.

VALUATION
84
very strong

The price looks reasonable next to what the company earns.

GROWTH
46
weak

Clearly below the class average.

PRICE MOMENTUM
35
weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 43% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
A fat but narrowing margin

The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $81.6762% above today’s price.

1
THE RISKS · 1/3
Sales are shrinking

Over the last 3 years, sales fell about 1% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 30/100.

3
THE RISKS · 3/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 35/100. For a turnaround signal, the stock first needs to close the gap with the market.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, PBH sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: PBH is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film